Loading…
The World Health Organization and its partners announced on 20 August 2026 that the Democratic Republic of the Congo will receive 70,000 doses of the Ervebo Ebola vaccine.
Of these, 50,000 doses go to front-line and health workers on WHO expert advice, while 20,000 are reserved for a Phase 3 trial testing whether the vaccine works against the Bundibugyo virus driving the outbreak.
The outbreak, declared in mid-May 2026 and now spread across six provinces of eastern Congo, had recorded 5,208 confirmed cases and 2,476 deaths, and is spreading about three times faster than the 2014-16 West Africa epidemic.
Ervebo is licensed against Zaire ebolavirus, not Bundibugyo virus, so its use here rests on early laboratory and animal data suggesting it may offer some cross-protection.
A first consignment of 16,250 doses reached Kinshasa on 22 August 2026.
Ervebo is built on a live, attenuated vesicular stomatitis virus that has been engineered to carry a single surface protein from Zaire ebolavirus. Because the vector is replication-competent, it multiplies in the body and provokes a strong immune response, but it contains only that one Ebola protein and no Ebola genome, so it cannot cause Ebola virus disease. The immune system learns to recognise that protein and is primed to attack the real virus if it appears. The limit of the design is also its logic: immunity is raised against a specific surface protein, so protection does not automatically extend to other members of the orthoebolavirus group, and offers nothing at all against the related orthomarburgviruses. The current outbreak is caused by the Bundibugyo virus, a different species from Zaire ebolavirus, which is exactly why 20,000 of the 70,000 doses have been set aside for a trial rather than simply deployed - WHO is testing an assumption, not applying a proven one.
Simple Analogy: A vaccine is a photograph handed to a security guard. Ervebo carries a sharp photograph of the Zaire virus; the intruder this time is a relative with a similar face, and the trial exists to find out whether the resemblance is close enough.
Ebola is first identified in southern Sudan and in what is now the Democratic Republic of the Congo.
The West Africa epidemic becomes the largest Ebola outbreak on record, driving the development and testing of Ervebo.
The European Commission grants Ervebo a conditional marketing authorisation.
WHO awards Ervebo prequalification status - the first vaccine ever prequalified for the prevention of Ebola virus disease.
The United States Food and Drug Administration approves Ervebo.
An Ebola outbreak caused by the Bundibugyo virus is declared in the Democratic Republic of the Congo.
WHO and partners announce 70,000 doses of Ervebo for the country - 50,000 for front-line and health workers, 20,000 for a Phase 3 trial.
A first consignment of 16,250 doses arrives in Kinshasa.
GS Paper 2 > Issues Relating to Health, and Important International Institutions; GS Paper 3 > Science and Technology: Developments in Biotechnology
General Awareness > General Science: Biology, Diseases and Vaccines; Current Affairs
Among the following, which were frequently mentioned in the news for the outbreak of Ebola virus recently?
Answer: Guinea, Sierra Leone and Liberia
A vaccine that uses a harmless or weakened virus to carry a gene for one protein of the target pathogen into cells, so the body produces that protein and mounts an immune response to it.
Able to multiply inside the host after administration. Ervebo's vesicular stomatitis virus vector replicates, which is why a single dose can generate strong immunity.
Weakened so that it provokes immunity without causing disease.
The current genus name for the group of viruses that cause Ebola disease, formerly ebolavirus. Zaire and Bundibugyo are distinct species within it.
A severe illness in which the virus damages blood vessels and disrupts clotting, causing bleeding alongside fever.
The large-scale stage of clinical testing in which a candidate is given to a substantial number of people to establish efficacy and monitor safety, usually the last step before licensure for a new indication.
WHO's assessment that a vaccine meets standards of quality, safety and efficacy, which allows United Nations agencies and national programmes to procure it.